Key result
Transcatheter ablation beats antiarrhythmic drugs for rhythm control and reduces mortality in heart failure.
Why the study?
Does transcatheter ablation improve outcomes compared to antiarrhythmic drugs in patients with atrial fibrillation?
Does transcatheter ablation improve outcomes compared to antiarrhythmic drugs in patients with atrial fibrillation?
This review highlights the evolving role of transcatheter ablation in managing atrial fibrillation, emphasizing its mortality benefits in patients with concurrent heart failure.
Answers are grounded in this paper and cite their sources.
May support ablation over drugs for rhythm control in AF-HF; leaves open mortality benefit confirmation in prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gaïta et al. (2023) conducted a review in Atrial fibrillation. Transcatheter ablation and antiarrhythmic drugs was evaluated. Transcatheter ablation is more effective than antiarrhythmic drugs for rhythm control and reduces mortality in patients with concurrent heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: